Navigation Links
New drug shows potential for treatment-resistant leukemia
Date:4/11/2011

BOSTON (April 11) --A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

Appearing in the journal Cancer Cell, the study is the first published report showing that the drug, DCC-2036, fights chronic myeloid leukemia (CML) in a mouse model of the disease and is effective against human leukemia cells.

"These findings demonstrate that DCC-2036 is an excellent candidate for clinical development as a treatment for resistant CML. Not all drugs that work in a test tube will actually be effective in a living organism such as our mouse model," said Richard Van Etten, MD, PhD, Director of Tuft's Medical Center's Cancer Center and senior author of the study.

Other authors of the study are scientists with Deciphera Pharmaceuticals LLC of Lawrence, Kansas, and Emerald Biostructures of Bainbridge Island, WA.

DCC-2036 is a tyrosine kinase inhibitor (TKI), a class of drugs that block the action of an abnormal enzyme, BCR-ABL1, that sends chemical messenges that tell CML cells to grow. The development of TKI drugs such as imatinib (Gleevec) dramatically improved the prognosis for patients with CML, which strikes about 5,000 new patients each year in the United States. But about a third of patients will eventually relapse, principally because of mutations that render BCR-ABL1 resistant to the TKI. Such patients are left with few treatment options other than bone marrow transplantation.

The study showed that in human cells taken from treatment-resistant patients who had received the new drug, DCC-2036 tamped down the mutant enzyme that led to their relapse. The study also found that the drug killed malignant cells and prolonged survival in a mouse model of CML developed by Van Etten's team.

Deciphera Pharmaceuticals, LLC used crystal structures of BCR-ABL1 to custom-design the novel drug to inhibit the mutant enzyme that leads to treatment resistance in CML patients. "The study illustrates the power of designing drugs based upon structures of the target and initial testing of these drugs in mouse models before proceeding to the clinic. This type of targeted design is a paradigm for how cancer treatments will be developed in the 21st century," Van Etten said.


'/>"/>

Contact: Julie Jette
jjette@tuftsmedicalcenter.org
617-636-3265
Tufts Medical Center
Source:Eurekalert

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trials
2. Warning labels better than a fat tax, University of Alberta study shows
3. Unemployment Plays Role in Early Deaths, Research Shows
4. Research shows blood protein levels may predict risk of a cardiovascular event: Study
5. Long-term study shows that kidney transplants are faring better than previously reported
6. New drug shrinks cancer in animals, U-M study shows
7. Simple chemical cocktail shows first promise for limb re-growth in mammals
8. Elevated levels of sodium blunt response to stress, study shows
9. Study shows that modern surgery for scoliosis has good long-term outcomes
10. Minimally Invasive Heart-Valve Procedure Shows Promise: Study
11. PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... States of America (PRWEB) , ... May 28, 2016 , ... ... SuperCloset knows all too well the day to day issues, struggles and obstacles ... military. The Helping Veterans Grow Project provides active or retired military veteran(s) with ...
(Date:5/28/2016)... ... ... In a part of the city where’s it’s easy to spot the neon lights of ... hoping to attract diners with a taste for real food. , On May 13, ... Cornerstone Grill, an urban casual restaurant focusing on dishes made by hand with wholesome, organic ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the maker ... been recognized as one of the best small businesses for new dads by Fatherly, ... nine small businesses providing progressive benefits to new parents on the organization’s 2016 ...
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the ... courtesy of leaders in the nursing and health care industry. It also provides insight ... Abilene Christian University. , As the nursing industry is coming out of one ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Nev. , May 24, 2016  Diana Russell ... "eats" her organs from the inside out.  This disease ... completely dependent on her children and grandchildren to leave ... her wheelchair, Diana,s family cannot haul the wheelchair.  So ... in the car, and Diana is left to wait ...
(Date:5/24/2016)... LAWRENCEVILLE, N.J. , May 24, 2016 /PRNewswire/ ... an oncology drug development company, today provided an ... Ib dose escalating clinical trial combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  GEN-1 is an IL-12 ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
Breaking Medicine Technology: